📅 IPO Timeline
- Bidding Period: September 1 – September 3, 2025
- Allotment Date: September 4, 2025
- Refunds & Demat Credit: Around September 5–8, 2025
- Listing Date: Expected on September 8 or 9, 2025 (BSE & NSE)
💰 Issue Structure
- IPO Type: Fresh issue of 1 crore equity shares
- Estimated Fund Raise: Up to ₹126 crore
- Face Value: ₹10 per share
- Price Band: ₹120 – ₹126
- Lot Size: Minimum 119 shares (approx. ₹14,994 at upper band)
- Investor Quota:
- QIBs – up to 50%
- NIIs – 15%
- Retail – 35%
📊 Use of IPO Proceeds
Funds will be utilized for:
- Setting up a new SteriPort line at the company’s plant in Gujarat (~₹70 crore)
- Installation of a small-volume parenteral (SVP) line (~₹30 crore)
- Remaining amount for general business needs
🏢 Company Profile
- Founded in 1994, Amanta Healthcare manufactures sterile liquid medicines such as LVPs (large-volume parenterals) and SVPs (small-volume parenterals).
- Supplies both Indian and global markets (exports to over 20 countries).
- Works with advanced manufacturing technologies like ABFS and ISBM.
📈 Financial Snapshot (FY25 vs FY24)
- Revenue: ₹276 crore (slightly down from ₹281 crore)
- Net Profit: ₹10.5 crore (up from ₹3.6 crore)
- Net Worth: ₹96 crore (₹66 crore in FY24)
- Margins: EBITDA ~22%; PAT margin ~3.9%
- ROE: 12.4% | ROCE: 13.7%
📊 Subscription Status
- Day 1: 4.6× subscribed – retail 6.7×, NIIs 5.8×, QIBs minimal
- Day 2: Around 16× – retail 20×, NIIs 28×, QIBs ~14% covered
- Day 3: Oversubscribed 23× overall
💹 Grey Market Premium (GMP)
- GMP fluctuated between ₹13–25 per share
- Indicates possible listing gains of 10–15%
🔎 Key Takeaways
- Solid growth in profitability with strong margins
- Focused use of IPO funds on expansion
- Healthy demand from retail and HNI investors
- Valuation slightly on the higher side (P/E ~46x)
